710 Medtronic Parkway, NE
Medtronic, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world.
Founders: Earl Bakken and Palmer Hermundlie
CEO: Omar Ishrak
CFO: Karen Parkhill
CSO (Scientific): Richard Kuntz
Please click here for Medtronic job opportunities.
Tweets by Medtronic
2111 articles with Medtronic
DUBLIN - March 14, 2019 - Medtronic plc announced that its Board of Directors has appointed Andrea J. Goldsmith, Ph.D. to the Board as an independent director, effective March 11, 2019.
VIVA Physicians Selects NAMSA as Statistical Analytic Group to Evaluate the Safety of Paclitaxel Drug-Eluting Technologies in PAD
VIVA Physicians announced the selection of NAMSA as the independent statistical analysis group to examine individual patient-level data associated with paclitaxel-coated balloons and stent trials used in the treatment of peripheral artery disease in the superficial femoral artery.
Board Authorizes $6 Billion for Share Repurchases
Medtronic Announces Closing of Public Offering of Senior Notes; Acceptance of Tendered Notes; and Redemption of Certain Senior Notes
Medtronic Global Holdings S.C.A. has closed a registered public offering of €500,000,000 principal amount of Floating Rate Senior Notes due 2021, €1,500,000,000 principal amount of 0.000% Senior Notes due 2021, €1,500,000,000 principal amount of 0.375% Senior Notes due 2023, €1,500,000,000 principal amount of 1.125% Senior Notes due 2027, €1,000,000,000 principal amount of 1.625% Senior Notes due 2031 and €1,000,000,000 principal amount of 2.250% Senior Notes due 2039.
Medtronic Global Holdings S.C.A., has priced an offering of €500,000,000 principal amount of floating rate senior notes due 2021, €1,500,000,000 principal amount of 0% senior notes due 2021, €1,500,000,000 principal amount of 0.375% senior notes due 2023, €1,500,000,000 principal amount of 1.125% senior notes due 2027, €1,000,000,000 principal amount of 1.625% senior notes due 2031, and €1,000,000,000 principal amount of 2.250% senior notes due 2039.
Medtronic Announces the Upsizing of its Maximum Tender Offers for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
Medtronic plc announced the upsizing of the previously-announced cash tender offers by its wholly-owned subsidiaries, Medtronic, Inc.
Medtronic plc, the global leader in medical technology, announced it will participate in the Barclays Global Healthcare Conference 2019 on Tuesday, March 12, 2019, in Miami, Florida.
Medtronic plc, the global leader in medical technology, announced it will participate in the 39th Annual Cowen and Company Healthcare Conference on Monday, March 11, 2019, in Boston, Massachusetts.
Medtronic Announces Approval and Launch of Japan's First DBM Bone Grafting Product for Spine and Orthopedic Procedures
Grafton(TM) DBM Product Will Provide More Options for Spine and Orthopedic Surgeons in Japan
MEDTRONIC ANNOUNCES FDA CLEARANCE AND U.S. LAUNCH OF THE ACCURIAN RADIO FREQUENCY SYSTEM FOR NERVE TISSUE ABLATION
Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Accurian™ RF ablation platform, which conducts radio frequency (RF) ablation of nerve tissues
Medtronic Resolute(TM) Drug-Eluting Stent (DES) Platform Receives Expanded Indication for Treatment of Chronic Total Occlusion (CTO)
FDA Approval Allows Interventional Cardiologists Access to Resolute DES Technology to Treat De Novo CTO
Medtronic Wraps Up Scientific Data Presentations at the Advanced Technologies and Treatments for Diabetes International Conference
Medtronic plc, the global leader in medical technology, announced a successful conclusion to the 12th International Conference on Advanced Technologies & Treatments for Diabetes, which took place in Berlin from February 20 - 23, 2019.
Medtronic EVP & RTG President Geoff Martha to Speak at Leerink Partners Global Healthcare Conference
Medtronic plc, the global leader in medical technology, announced it will participate in the 8th Annual Leerink Partners Global Healthcare Conference in New York.
Medtronic Announces U.S. Commercial Launch of Deep Brain Stimulation for Medically-Refractory Epilepsy
With Official Launch and First Implant, Several Health Insurers Now Consider
Medtronic Announces Cash Tender Offer for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
Medtronic plc announced the commencement of a cash tender offer by its indirectly wholly owned subsidiaries
Medtronic Receives FDA Breakthrough Designation for Developing Personalized Closed Loop Insulin Pump System for Diabetes Management
Medtronic plc, the global leader in medical technology, announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration for its Personalized Closed Loop insulin pump system, currently in development.
Medtronic plc announced financial results for its third quarter of fiscal year 2019, which ended January 25, 2019.
Medtronic Announces Preliminary PRODIGY Results: a Global Study to Identify Patients at High Risk for Opioid-Induced Respiratory Compromise
Study Found Greater Than 40 Percent of Patients on Hospital General Care Floor Experience Opioid- Induced Respiratory Depression
Medtronic plc (NYSE:MDT) and the Medical University of South Carolina (MUSC) today announced a five-year value-based health care partnership intended to transform and improve care for patients in South Carolina.
Approval Based on Clinical Data from the PREMIER Trial - New Indication Provides Options for Patients with Small or Medium, Wide-Necked Brain Aneurysms